Biotech Values

[DewDiligence]

PTLA red flag: Management wants to amend the SAP for the phase-3 APEX study of Betrixaban, despite the fact that the trial is 50% enrolled. Sounds like they don’t think the trial will hit the primary endpoint on the total population and are already trying to make an argument for subset data. (Source: Today's 2Q14 CC.)